Vir Biotechnology has released the topline data from its Phase 2 PENINSULA trial, which evaluated VIR-2482 for the prevention of seasonal influenza A illness.
According to the announcement made on July 20, 2023, VIR BIOTECHNOLOGY Inc. reported that the trial did not meet its primary or secondary efficacy endpoints.
In participants who received the highest dose of VIR-2482 (1,200 mg), there was a non-statistically significant reduction of approximately 16% in influenza A protocol-defined illness.
However, when symptomatic influenza A illness was defined according to CDC influenza-like-illness criteria, participants who received the highest dose showed an approximately 57% reduction.
Overall, VIR-2482 was well tolerated by participants and no safety concerns were identified during the trial.